1. Home
  2. MDXH vs MCRB Comparison

MDXH vs MCRB Comparison

Compare MDXH & MCRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MDxHealth SA

MDXH

MDxHealth SA

HOLD

Current Price

$2.30

Market Cap

149.0M

Sector

N/A

ML Signal

HOLD

Logo Seres Therapeutics Inc.

MCRB

Seres Therapeutics Inc.

HOLD

Current Price

$8.81

Market Cap

139.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MDXH
MCRB
Founded
2003
2010
Country
Belgium
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
149.0M
139.7M
IPO Year
2021
2015

Fundamental Metrics

Financial Performance
Metric
MDXH
MCRB
Price
$2.30
$8.81
Analyst Decision
Strong Buy
Buy
Analyst Count
3
2
Target Price
$7.67
$14.00
AVG Volume (30 Days)
156.6K
42.7K
Earning Date
05-13-2026
03-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.64
Revenue
N/A
$789,000.00
Revenue This Year
$30.78
N/A
Revenue Next Year
$18.31
N/A
P/E Ratio
N/A
$13.75
Revenue Growth
N/A
N/A
52 Week Low
$1.36
$0.36
52 Week High
$5.33
$29.98

Technical Indicators

Market Signals
Indicator
MDXH
MCRB
Relative Strength Index (RSI) 18.64 44.12
Support Level $1.90 $7.74
Resistance Level $2.30 $9.53
Average True Range (ATR) 0.20 0.68
MACD -0.10 0.17
Stochastic Oscillator 3.45 52.74

Price Performance

Historical Comparison
MDXH
MCRB

About MDXH MDxHealth SA

MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.

About MCRB Seres Therapeutics Inc.

Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.

Share on Social Networks: